К ВОПРОСУ МОРФОЛОГИЧЕСКОГО ИССЛЕДОВАНИЯ ОПУХОЛЕЙ НАДПОЧЕЧНИКОВ
Ключевые слова:
адренокортикальные опухоли, феохромоцитома, морфологическое исследование надпочечников, иммуногистохимическое исследованиеАннотация
Дифференциальная диагностика доброкачественных и злокачественных образований надпочечников представляет определенные трудности, поскольку не существует какого-либо конкретного гистологического критерия, позволяющего дифференцировать опухоли коры надпочечника со злокачественным клиническим течением. В настоящее время для дифференциации доброкачественных опухолей и адренокортикальных карцином предложены несколько мультипараметрических систем оценки результатов гистопатологических исследований. Точность той или иной из предложенных систем остается предметом дискуссий. В статье подробно описываются различные шкалы для оценки вероятности озлокачествления опухолей надпочечников. Отмечена основополагающая роль иммуногистохимического исследования с использованием достаточно широкого спектра маркеров для завершения классического гистологического анализа.
Библиографические ссылки
Бабич, А.И. Современные подходы к диагностике и лечению адренокортикального рака: дис. ... канд.мед.наук.: 14.01.17, 14.01.12 / Бабич Александр Игоревич. - С-Пб, 2015. - 191 с.
Костин, А.А. Результаты хирургического лечения больных опухолями надпочечников / А.А. Костин, Н.В. Воробьев, А.О. Толкачев и др. // Исследования и практика в медицине. - 2016. - Том 3, № 4. - С.19-26.
Филиппова, Адренокортикальный рак: клинические проявления и морфологическая диагностика / О.В. Филиппова, Н.М. Хмельницкая // Медицинский Альманах.- 2011.- №5 (18) .- С.113-116.
AgarwalA,Mehrotra PK,Jain M, GuptaSK, MishraA,ChandG, Agarwal G, Verma AK, Mishra SK, Singh U. Size of the tumor andpheochromocytoma ofthe adrenal gland scaled score(PASS): can they predict malignancy? World J Surg 34:3022-3028, 2010.
Agrons GC, Lonergan GJ, Dickey GE, Perez-Monte JE. Adrenocortical neoplasms in children: radiologic-pathologic correlation. Radiographics 1999;19:989-1008.
Arola J, Salmenkivi K, Liu J, et al. P53 and Ki-67 in adrenocortical tumors. Endocr Res. 2000;26:861-865.
Aubert S, Wacrenier A, Leroy X, Devos P, Carnaille B, et al. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol 2002;26:1612-1619.
Berthon A, Martinez A, Bertherat J, Val P. Wnt/Β-catenin signalling in adrenal physiology and tumour development. Mol Cell Endocrinol. 2012;351:87-95.
Berthon A, Sahut-Barnola I, Lambert-Langlais S, de Joussineau C, Damon Soubeyrand C, Louiset E, et al. Constitutive Β-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Hum Mol Gen. 2010;19:1561-1576.
Beuschlein F, Weigel J, Saeger W, Kroiss M, Wild V, Daffara F, Libé R, Ardito A, Al Ghuzlan A, Quinkler M, Oßwald A, Ronchi CL, de Krijger R, Feelders RA, Waldmann J, Willenberg HS, Deutschbein T, Stell A, Reincke M, Papotti M, Baudin E, Tissier F, Haak HR, Loli P, Terzolo M, Allolio B, Müller HH, Fassnacht M. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J Clin Endocrinol Metab 100: 841-849, 2015.
Blanes, A. Histologic criteria for adrenocortical proliferative lesions: value of mitotic figure variability / A. Blanes, S.J. Diaz-Cano // Am. J. Clin.Pathol. - 2007. - Vol. 127. - P. 398-408.
Bugg MF, Ribeiro RC, Roberson PK, Lloyd RV, Sandrini R, et al. Correlation of pathologic features with clinical outcome in pediatric adrenocortical neoplasia. A study of a Brazilian population. Brazilian Group for Treatment of Childhood Adrenocortical Tumors. Am J Clin Pathol 1994;101:625-9.
Cagle PT, Hough AJ, Pysher TJ, Page DL, Johnson EH, et al. Comparison of adrenal cortical tumors in children and adults. Cancer 1986;14:2235-2237.
Chatterjee G, DasGupta S, Mukherjee G, Sengupta M, Roy P, et al. Usefulness of Wieneke criteria in assessing morphologic characteristics of adrenocortical tumors in children. Pediatr Surg Int 2015;31:563-71.
Custodio G, Parise GA, Filho NK, Komechen H, Sabbaga CC, Rosati R, et al. Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors. J Clin Oncol. 2013;31:2619-2627.
de Krijger, R. Adrenocortical neoplasia: evolving concepts in tumorigenesis with an emphasis on adrenal cortical carcinoma variants / R. de Krijger, T. Papathomas // Virchows Archive. – 2012. – Vol. 460, N 1. – P. 9-18.
Dichtchekenian V, de Bragança Pereira CA, Kuperman H, Della Manna T, Damiani D, et al. Adrenocortical carcinoma: prognostic indices based on clinical and immunohistochemical markers. J Pediatr Endocrinol Metab 2005;18:347-53.
Drelon C, Berthon A, Val P. Adrenocortical cancer and IGF2: is the game over or our experimental models limited? J Clin Endocrinol Metab. 2013;98:505-507.
Duregon E, Fassina A, Volante M, Nesi G, Santi R, Gatti G, et al. The reticulin algorithm for adrenocortical tumor diagnosis: a multicentric validation study on 245 unpublished cases. Am J Surg Pathol. 2013;37:1433-40.
Duregon E, Molinaro L, Volante M, Ventura L, Righi L, Bolla S, Terzolo M, Sapino A, Papotti MG. Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phosphohistone H3 mitotic count and Ki-67 index in adrenocortical carcinoma. Mod Pathol 27: 1246-1254, 2014.
Dy, B.M. Operative intervention for recurrent adrenocortical cancer / B.M. Dy, K.B.Wise, M.L.Richards et al. // Surgery. - 2013. - Vol. 154. - P. 1292-1299.
Evans, HL. Adrenal cortical neoplasms A study of 56 cases. / H.L. Evans, R.Vassilopoulou-Sellin // Am J Clin Pathol. – 1996. – Vol. 105. – P. 76-86.
Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab (2013) 98:4551-4564.
Fassnacht M, Libé R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician’s update. Nat Rev Endocrinol 2011;7:323-335.
Figueiredo BC, Sandrini R, Zambetti GP, Pereira RM, Cheng C, Liu W, et al. Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation. J Med Genet. 2006;43:91-96.
Gaujoux S, Grabar S, Fassnacht M, Ragazzon B, Launay P, Libe R, et al. Β-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clin Cancer Res. 2010;17:328-336.
Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, Baudin E, et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res. 2001;61:6762-7.
Heaton JH, Wood MA, Kim AC, Lima LO, Barlaskar FM, Almeida MQ, et al. Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and Β-catenin. Am J Pathol. 2012;181:1017-1033.
Herrmann LJM, Heinze B, Fassnacht M, Willenberg HS, Quinkley M, Reisch N, et al. TP53 germline mutations in adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2012;97:e476-485.
Herrmann LJM, Heinze B, Fassnacht M, Willenberg HS, Quinkley M, Reisch N, Higgins SE, Barletta JA. Applications of immunohistochemistry to endocrine pathology. Adv Anat Pathol 2018; 25:413-429.
Hough AJ, Holifield JW, Page DL, et al: Prognostic factors in adrenal cortical tumors. A mathematical analysis of clinical and morphologicdata. AmJClinPathol 72:390-400, 1979.
Ip JC, Pang TC, Glover AR, et al. Immunohistochemical validation of overexpressed genes identified by global expression microarrays in adrenocortical carcinoma reveals potential predictive and prognostic biomarkers. Oncologist. 2015;20:247-256.
Johanssen S, Hahner S, Saeger W, Quinkler M, Beuschlein F, Bralle H, et al. Deficits in the management of patients with adrenocortical carcinoma in Germany. Dtsch Arztebl Int. 2010;107:885-91.
Kimura N, Takayanagi R, Takizawa N, Itagaki E, Katabami T, Kakoi N, Rakugi H, Ikeda Y, Tanabe A, Nigawara T, Ito S, Kimura I, Naruse M; Phaeochromocytoma Study Group in Japan. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer 21: 405-414, 2014.
Kimura N, Takekoshi K, Horii A, Morimoto R, Imai T, Oki Y, Saito T, MidorikawaS, AraoT, Sugisawa C,YamadaM, OtukaY, Kurihara I, Sugano K, Nakane M, Fukuuchi A, Kitamoto T, Saito J, Nishikawa T, Naruse M. Clinicopathological study of SDHB mutation-related pheochromocytoma and sympathetic paraganglioma. Endocr Relat Cancer. 21: L13-L16, 2014.
Kimura N, Watanabe T, Noshiro T, Shizawa S and Miura Y. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocr Pathol 16: 23-32, 2005.
Lalli E, Figueiredo BC. Pediatric Adrenocortical tumors: what they can tell us on adrenal development and comparison with adult adrenal tumors. Front Endocrinol (Lausanne) 2015;6:1-9.
Lau SK, Weiss LM. The Weiss system for evaluating adrenocortical neoplasms: 25 years later. Hum Pathol. 2009;40:757-68.
Lloyd RV, Osamura RY, Kloppel G, Rosai J. WHO classification of tumours: pathology and genetics of tumours of endocrine organs. 4th ed. Lyon: IARC; 2017. - P 641-664.
Mete O, Gucer H, Kefeli M, et al. Diagnostic and prognostic biomarkers of adrenal cortical carcinoma. Am J Surg Pathol. 2018;42:201-213.
Mlika M, Kourda N, Zorgati MM, Bahri S, Ben Ammar S, ZermaniR. Prognostic value of pheochromocytoma of the adrenal gland scaled score (PASS score) tests to separate benign from malignant neoplasms. Tunis Med 91: 209-215, 2013.
Morimoto R, Satoh F, Murakami O, Suzuki T, Abe T, et al. Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr J 2008;55:49-55.
Papathomas TG, Pucci E, Giordano TJ, et al. An international ki67 reproducibility study in adrenal cortical carcinoma. Am J Surg Pathol. 2016;40:569-576.
Papotti M, Libè R, Duregon E, Volante M, Bertherat J, Tissier F. The Weiss score and beyond-histopathology for adrenocortical carcinoma. Horm Cancer. 2: 333-340, 2011.
Parenti G, Zampetti B, Rapizzi E et al (2012) Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma. J Oncol 2012:872713.
Patterson E, Webb R, Weisbrod A, Bian B, He M, Zhang L, Holloway AK, KrishnaR, Nilubol N, Pacak K, Kebebew E. The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma. Endocr Relat Cancer 19: 157-166, 2012.
Pennanen, M. Helsinki score - a novel model for prediction of metastases in adrenocortical carcinomas / M. Pennanen, I.Heiskanen, T. Sane et al. // Human Pathology. - 2015. - Vol. 46, N 3. - P. 404-410.
Ragazzon B, Libe R, Gaujoux S, Assie G, Fratticci A, Launay P, et al. Transcriptome analysis reveals that p53 and Β-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res. 2010;70:8276-8281.
Reincke M, Karl M, Travis WH, Mastorakos G, Allolio B, Linehan HM, et al. Р53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J Clin Endocrinol Metab. 1994;78:790-794.
Ribeiro RC, Sandrini Neto RS, Schell MJ, Lacerda L, Sambaio G, et al. Adrenocortical carcinoma in children: a study of 40 cases. J Clin Oncol 1990;8:67-74.
Sasano H, Suzuki T, Moriya T. Discerning malignancy in resected adrenocortical neoplasms. Endocr Pathol. 2001;12:397-406.
Sbragia L, Sbragia L, Oliveira-Filho AG, Oliveira-Filho AG, Vassallo J, et al. Adrenocortical tumors in Brazilian children: immunohistochemical markers and prognostic factors. Arch Pathol Lab Med 2005;129:1127-31.
Schmitt A, Saremaslani P, Schmid S, Rousson V, Montani M, Schmid DM, et al. IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumors. Histopathology. 2006;46:298-307.
Soon PS, Gill AJ, Benn DE, et al. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify igf2 and ki-67 as useful in differentiating carcinomas from adenomas. Endocr Relat Cancer. 2009;16:573-583.
Soon PSH, Libe R, Benn DE, Gill A, Shaw J, Sywak MS, et al. Loss of heterozygosity of 17p13, with possible involvement of ACADVL and ALOX15B, in the pathogenesis of adrenocortical tumors. Ann Surg. 2008;247:157-64.
Stojadinovic A, Ghassein RA, Hoos A, Nissan A, Marshall D, Dudas M, et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol. 2002;20:941-950.
Thiel A, Reis AC, Haase M, Goh G, Schott M, Willenberg HS, Scholl UI. PRKACA mutations in cortisol-producing adenomas and adrenal hyperplasia: a single-center study of 60 cases. Eur J Endocrinol 172: 677-685, 2015.
Thompson LD. Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 26: 551–566, 2002.
Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, Hagnere A, et al. Mutations of Β-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 2005;65:7622-7627.
Van Slooten H, Schaberg A, Smeenk D, et al: Morphologic characteristics of benign and malignant adrenocortical tumors. Cancer 55: 766–772, 1985.
Vargas MP, Vargas HI, Kleiner DE, et al. Adrenocortical neoplasms: role of prognostic markers mib-1, p53, and rb. Am J Surg Pathol. 1997;21:556-562.
Volante M, Bollito E, Sperone P, Tavaglione V, Daffara F, Porpiglia F, et al. Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. Histopathology. 2009;55:535–43.
Waldmann J, Patsalis N, Fendrich V, Langer P, Saeger W, Chaloupka B, et al. Clinical impact of TP53 alterations in adrenocortical carcinomas. Langenbecks Arch Surg. 2012;397:209-216.
Wasserman, J.D. Towards an understanding of the role of p53 in adrenocortical carcinogenesis / J.D.Wasserman, G.P. Zambetti, D.Malkin // Molecular and Cellular Endocr. - 2012. - Vol. 351. - P. 101-110.
Weiss LM, Medeiros J, Vickery AL. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol. 1989;13:202-6.
Weiss, L.M. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors / L.M. Weiss // Am. J. Surg. Pathol. - 1984. - Vol. 8, №3. - P. 163-169.
Weissferdt A, Phan A, Suster S, et al. Adrenocortical carcinoma: a comprehensive immunohistochemical study of 40 cases. Appl Immunohistochem Mol Morphol. 2014;22:24-30.
Wieneke JA, Thompson LD, Heffess CS. Adrenal cortical neoplasms in the pediatric population. Am J Surg Pathol 2003;27:867-881.
